Lipid Nanoparticle (LNP) Drug Delivery Advances, April 7-14, 2025

Apr 14, 2025

2 min read

News Summary

University of Pennsylvania: Developed nitro-oleic acid-modified LNPs for safer plasmid DNA delivery, enabling long-term gene expression in mice.

ACS Biochemistry Study: Introduced click chemistry LNPs for targeted mRNA delivery to metabolically labeled cancer cells.

Marama Labs: Launched CloudSpec, a tool for rapid lipid nanoparticle analysis, reducing lab times from hours to seconds.

Global Market Report: Projected lipid nanoparticle market growth to US$2.39 billion by 2032, driven by mRNA vaccines and biologics.

Nature Biomedical Engineering: Reported LNPs with PDL1-encoding mRNA to induce immune tolerance in rheumatoid arthritis models.

ACS Nano: Detailed post-encapsulation method for mRNA-LNP preparation, enhancing personalized medicine applications.

AI-Enabled RNA–LNP Discovery: Highlighted advancements in AI tools for accelerating RNA and lipid nanoparticle development pipelines.

Detailed News Summaries

University of Pennsylvania: Safer Plasmid DNA Delivery via Modified LNPs

Release Date: April 7, 2025

Website Link: https://www.bioanalysis-zone.com/breakthrough-in-dna-delivery-modified-lipid-nanoparticles-enable-safer-gene-expression/

Authors: Manthan N. Patel, Sachchidanand Tiwari et al.

Related Institution: Perelman School of Medicine, University of Pennsylvania (Philadelphia, PA, USA)

By incorporating nitro-oleic acid (NOA) into LNPs, researchers inhibited the cGAS-STING pathway, reducing inflammation in mice. NOA-pDNA-LNPs achieved 11.5-fold higher transgene expression than mRNA-LNPs at 32 days post-administration.

ACS Biochemistry Study: Click Chemistry LNPs for Cancer Targeting

Bioorthogonal “click” chemistry enables targeted mRNA delivery: DBCO-modified LNPs selectively bind azide-labeled cancer cells for precise, cell-specific therapy.

Release Date: April 7, 2025

Website Link: https://pubs.acs.org/doi/abs/10.1021/acs.biochem.4c00699

Authors: Zhengzhong Tan, Lining Zheng et al.

Related Institution: University of Illinois Urbana-Champaign (Urbana, IL, USA)

LNPs functionalized with dibenzocyclooctyne (DBCO) lipids selectively delivered mRNA to azide-labeled cancer cells via bioorthogonal chemistry, achieving 50-fold higher expression than non-targeted LNPs.

Marama Labs: CloudSpec for Rapid LNP Analysis

Release Date: April 10, 2025

Website Link: https://www.emjreviews.com/emj-gold/news/cloudspec-lipid-nanoparticle-accelerates-drug-development/

Authors: Brendan Darby, Darren Andrews

Related Institution: Marama Labs (Dublin, Ireland)

CloudSpec’s Scatter-Free Absorption technology analyzes intact LNPs in 15 seconds, eliminating fluorescent dyes. Early adopters reported streamlined workflows for gene therapy and vaccine development.

Global Lipid Nanoparticles Market Report

Release Date: April 9, 2025

Website Link: https://www.taiwannews.com.tw/news/6080763

The market is projected to grow at a 12.6% CAGR, reaching US$2.39 billion by 2032. Drivers include mRNA vaccine demand, biologics adoption, and advancements in targeted delivery.

Nature Biomedical Engineering: Tolerogenic LNPs for Autoimmunity

Release Date: April 11, 2025

Author: Maria Papatriantafyllou

Website Link: https://www.nature.com/articles/s41584-025-01251-8

Subcutaneous administration of stealth LNPs encoding PDL1 induced tolerogenic antigen-presenting cells, suppressing effector T cells in rheumatoid arthritis models.

ACS Nano Study on Post-Encapsulation mRNA-LNP Preparation Methodology

Post-encapsulation of mRNA into mRNA-free LNPs

Release Date: April 12

Website link: https://pubs.acs.org/doi/10.1021/acs.nanolett.4c06643

Authors: Hiroki Tanaka, Yuka Sato et al.

This study introduces novel encapsulation methods improving stability, scalability, and personalized medicine applications.

University of Toronto: AI-Enabled RNA-LNP Discovery

Release Date: April 11, 2025

Website Link: The future is now: AI-enabled RNA–LNP discovery

Authors: Charlotte Barker (Commissioning Editor, Vaccine Insights), Bowen Li (Assistant Professor, University of Toronto)

Related Institution: University of Toronto (Toronto, Canada)

Researchers at the University of Toronto’s LUMI-lab developed an AI-driven platform to design LNPs for RNA delivery. The platform combines machine learning with high-throughput screening to optimize lipid compositions for tissue-specific targeting. The approach accelerates the discovery of LNPs for extrahepatic organs, including the brain and immune cells, while minimizing toxicity risks.